| Before baseline screening | Baseline | Visit 1 Treatment phase | Visit 2 Treatment phase | Visit 3 Follow-up phase |
---|---|---|---|---|---|
Process items | Â | 0Â day | 3Â weeks | 6Â weeks | 12Â weeks |
Patients | Â | Â | Â | Â | Â |
 Inclusion and exclusion criteria | × |  |  |  |  |
 Informed consent |  | × |  |  |  |
 Demographics |  | × |  |  |  |
 Medical history | × | × |  |  |  |
 Randomization and allocation concealment |  | × |  |  |  |
Primary outcomes | Â | Â | Â | Â | Â |
 Grading of dermatologic toxicity |  | × | × | × | × |
 Objective skin, nail, and tongue color (L*a*b) |  | × | × | × | × |
Secondary outcomes | Â | Â | Â | Â | Â |
 Fatigue measurement score |  | × | × | × | × |
 Routine blood test (WBC, HGB, PLT) |  | × | × | × | × |
 Liver function (ALT, AST, total protein, Alba) |  | × | × | × | × |
 Renal function (Cr and BUN) |  | × | × | × | × |
Adverse events |  |  | × | × | × |
Patients’ diary records |  | Every day during the study |